As the senior director of United States marketing for Vera Therapeutics, Dara Keian Dayani manages all aspects of atacicept in IgA Nephropathy (IgAN) brand strategy, which includes go-to-market planning and launch readiness strategies. He leads cross-functional teams through matters of sales, medical affairs, patient support, and other areas. Dara Keian Dayani is further tasked with the development of core US commercial resources and strategic models, product positioning, brand messaging, for both HCP and patient audiences.
Keian Dayani has extensive experience in the nephrology and rare disease landscape. Before joining Vera Therapeutics in 2025, he served in roles such as director of Pfizer Oncology and director of Seagen. He initially joined Seagen as a senior manager in 2019, during which time he functioned as the global market insights lead for ADCETRIS.
Keian Dayani holds a doctor of pharmaceutical science from Northeastern University in Boston. He received a dean’s scholarship and honors distinction during his time at the school. He also holds a master of business administration from the University of Washington.